Celemics Inc is a Korea-based company mainly engaged in manufacturing products related to life science medicine. The Company mainly develops and sells target capture kit products. In addition, the Company is engaged in immune repertoire analysis solutions and next-generation sequencing solutions. The Company sells its products in domestic and overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
28/08/26	₩12,950.00	+18.92%	599,871
27/08/26	₩10,890.00	+29.95%	590,666
26/08/26	₩8,380.00	-3.34%	29,302
25/08/26	₩8,670.00	-2.58%	47,788
24/08/26	₩8,900.00	+3.49%	40,395

End-of-day quote Korea S.E.

More quotes

Annual profits - Rate of surprise

Company calendar

End-of-day quote Korea S.E. 28/08/2026			5-day change	1st Jan Change
12,950.00 ^KRW	+18.92%		+50.58%	+376.98%

06-23	Celemics, Inc. announced that it expects to receive KRW 9.999995577 billion in funding from Cnp Co., Ltd.	CI
05-28	Celemics, Inc. announced that it has received KRW 11.5999945 billion in funding	CI

Market Cap	145B 105M 90.53M 84.88M 77.49M 146M 10.04B 146M 1.01B 393M 5.07B 394M 386M 16.81B	P/E 2024	2.19x	P/E 2025	-5.49x
Enterprise Value	139B 101M 87.07M 81.64M 74.52M 140M 9.66B 141M 969M 378M 4.87B 379M 371M 16.16B	EV / Sales 2024	2.56x	EV / Sales 2025	2.88x
Free-Float	-	Yield 2024 *	-	Yield 2025	-

06-23	Celemics, Inc. announced that it expects to receive KRW 9.999995577 billion in funding from Cnp Co., Ltd.	CI
05-28	Celemics, Inc. announced that it has received KRW 11.5999945 billion in funding	CI
04-29	Celemics, Inc. announced that it has received KRW 8.292707441 billion in funding	CI
04-27	Celemics, Inc. announced that it has received KRW 14.7 billion in funding	CI
03-30	Celemics, Inc. announced that it expects to receive KRW 11.5999945 billion in funding	CI
03-29	Celemics, Inc. announced that it expects to receive KRW 27 billion in funding	CI
03-12	Park Jong-gap completed the acquisition of an additional 5.27% stake in Celemics, Inc. from Kim Hyo-gi, Lee Yong-hoon.	CI
02-02	Celemics, Inc. announced that it expects to receive KRW 9.2927074 billion in funding	CI
02-02	Park Jong-gap agreed to acquire an additional 5.27% stake in Celemics, Inc. from Hyo-gi Kim, Yong-hoon Lee for KRW 2.6 billion.	CI
19/09/22	Celemics, Inc.(KOSDAQ:A331920) dropped from S&P Global BMI Index	CI
22/03/21	Celemics, Inc.(KOSDAQ:A331920) added to S&P Global BMI Index	CI
21/08/20	Celemics, Inc. has completed an IPO in the amount of KRW 26.4 billion.	CI
18/03/20	Celemics, Inc. has filed an IPO.	CI

1 day	+18.92%
1 week	+50.58%
Current month	+43.09%
1 month	+42.15%
3 months	-24.22%
6 months	+161.35%
Current year	+376.98%

Celemics, Inc. Share Price

Stocks

A331920

KR7331920009

Biotechnology & Medical Research

Valuation : Celemics, Inc.

Chart: Celemics, Inc.

Latest news : Celemics, Inc.

Press Releases : Celemics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Celemics, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	8,270	13,650
1 month	8,240	13,650
Current year	2,580	19,840
1 year	2,535	19,840
3 years	2,535	19,840
5 years	2,535	20,900
10 years	2,535	39,400

Manager	Title	Age	Since
Yong-Hun Lee CEO	Chief Executive Officer	61	31/12/2016
Hyo-Gi Kim CEO	Chief Executive Officer	43	31/12/2012
Sang-Seok Lee PRN	Corporate Officer/Principal	45	31/12/2019

Director	Title	Age	Since
Hyo-Gi Kim BRD	Director/Board Member	43	31/12/2012
Yong-Hun Lee BRD	Director/Board Member	61	31/12/2016
Sang-Seok Lee BRD	Director/Board Member	45	31/12/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELEMICS, INC.	+18.92%	+50.58%	+337.50%	+185.87%	105M
LONZA GROUP AG	-0.78%	-1.42%	+2.96%	+21.65%	50.47B
REVOLUTION MEDICINES, INC.	-6.00%	-0.75%	+447.48%	+535.14%	44.56B
IQVIA HOLDINGS INC.	-0.24%	+0.74%	+37.18%	+16.26%	43.08B
BEONE MEDICINES AG	-1.55%	-2.07%	+19.83%	+71.70%	41.7B
CELLTRION, INC.	-0.31%	-0.83%	+19.47%	+48.24%	33.21B
MEDPACE HOLDINGS, INC.	-1.79%	-3.24%	+26.32%	+125.06%	16.77B
ASCENDIS PHARMA A/S	-0.58%	-2.12%	-	-	16.28B
EUROFINS SCIENTIFIC SE	-0.88%	-0.66%	+11.63%	+27.62%	14.58B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.66%	-1.25%	+78.49%	+42.97%	13.92B
Average	+0.51%	+3.60%	+108.99%	+119.39%	27.47B
Weighted average by Cap.	-1.69%	-1.04%	+96.38%	+129.06%

	2024	2025
Net sales	6.72B 4.88M 4.2M 3.94M 3.6M 6.77M 466M 6.79M 46.73M 18.23M 235M 18.3M 17.91M 780M	5.77B 4.18M 3.61M 3.38M 3.09M 5.81M 400M 5.83M 40.11M 15.65M 202M 15.71M 15.37M 669M
Net income	12.27B 8.9M 7.67M 7.19M 6.56M 12.37M 851M 12.41M 85.31M 33.29M 429M 33.42M 32.69M 1.42B	-4.04B -2.93M -2.52M -2.37M -2.16M -4.07M -280M -4.08M -28.07M -10.95M -141M -11M -10.76M -469M
Net Debt	-9.55B -6.93M -5.97M -5.6M -5.11M -9.63M -662M -9.66M -66.41M -25.91M -334M -26.01M -25.44M -1.11B	-5.54B -4.02M -3.46M -3.25M -2.96M -5.58M -384M -5.6M -38.53M -15.03M -194M -15.09M -14.76M -643M